DOCSLIB.ORG

United States Patent Office Patented June 16, 1964

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent Office Patented June 16, 1964 3,137,625 United States Patent Office Patented June 16, 1964 1 2 3,137,625 low those which cause disturbing side effects and yet DIURETHI COMBINATIONS €ONTAENHNG A maximum diuresis and electrolyte excretion obtained with TiHAZIDE AND A MERCURlAL out gastro-intestinal irritation. John H. Biel, Milwaukee, Wis, assignor to Lakeside The use of a thiazide diuretic in‘ combination with a Laboratories, Inc, Milwaukee, Wis, a corporation of .mercurial diuretic effects the increased diuresis while Delaware 7 actually reducing potassium excretion, thus greatly in No Drawing. Filed Jan. 9, 1961, Ser. No. 81,244 creasing the safety margin for this type of therapy. The 4 Claims. (Cl. 167-65) mercurial diuretic apparently inhibits the increased potas sium output normally produced by a thiazide diuretic. This invention relates to the treatment of humans. 10 The combination of a thiazide diuretic and a mercurial More particularly, this invention is concerned with a diuretic thus provides safe, maximum diuretic therapy and novel method of inducing diuretic activity in humans, sodium chloride excretion with a minimum of side effects and novel pharmaceutical compositions useful therein. and thus is a major advance in the treatment of congestive There are on the market various diuretics of the heart failure, edema, high blood pressure and glaucoma. “thiazide” type, viz., those containing the 7-sulfamoyl By using the diuretic combination of this invention the 2H-1,2,4-benzothiadiaZine-l,l-dioxide or 7-sulfamoyl greatest reduction in amount of diuretic needed is in the 2H-3,4-dihydro-1,2,4-benzothiadiazine-1, l-dioxide nucleus, mercurial component rather than in the thiazide. The including chlorothiazide, dihydrochlorothiazide, dihydro gastro-intestinal side e?ects incident to the higher mer v?umethiazide, benzydro?umethiazide, methylchlorothiaz curial dosage is thus essentially eleminated. However, ide and trichloromethiazide. Chlorothalidone (Hygroton, 20 the amount of mercurial used in the combination never Ciba), while it contains a nucleus somewhat different than theless suppresses the potassium excretion usually induced that of the thiazides just described is a sulfonamide-con by the thiazide diuretic while simultaneously increasing taining diuretic and for the purpose of this invention is diuresis over that obtainable by use of the thiazide alone. to be considered Within the terminology used when thiaz The combination of a thiazide diuretic with a mer ide diuretics are mentioned. Such compounds, and others 25 curial diuretic is advisably formulated into suitable phar 'of the thiazide type, are orally effective and increase di maceutical unit dosage forms such as tablets and cap uretic activity in humans at daily dosage amounts of from about 4 to 300 mgm. sules. Carriers can be used as desired to achieve a suit able volume to dosage relationship to facilitate ease of Although the thiazide type of diuretic is orally active handlingthe unit dosage form. Such formulating is with— and readily absorbed from the gastrointestinal tract, there 30 in the skill of the pharmaceutical chemist. are three major disadvantages involved with their use. The amount of thiazide diuretic and mercurial di The ?rst is that the thiazide diuretics do not eliminate retic used in the combination will be goverened by the all of the excess fluid and sodium electrolyte but usually activity of the particular drug used since the activity varies leave a 20% excess residue of sodium and water. They from one to the other. The following, however, are par thus do not usually bring a cardiac patient down to “dry 35 ticular dosage combinations which can be used: Weight." This is particularly disturbing in the more severe cardiac patient. Due to the ?at dose-response curve ob Mg. tained with the thiazide type diuretics, not even larger (A) dosages can rid the body of this excess residue. Sec Trichloromethiazide ____________________ __ 1 to 10 Chlormerodrin ________________________ __ 1 to 30 ondly, thiazide diuretics eliminate not only excess sodium 40 ion, which is desirable, but also increased amounts of (B) potassium which in highly undesirable and can lead to Chlorothiazide _________________________ __ 50 to 500 death, in some cases, due to a potassium de?ciency. Chlormerodrin ________________________ __ 1 to 40 Thirdly, prolonged administration of large doses of thiaz (C) ide diuretics can produce a gouty arthritis which necessi 45 Dihydrochlorothiazide __________________ __ 10 to 100 tates withdrawal of the drug. ' Chlormerodrin ________________________ __ 1 to 40 In addition to the thiazide diuretics, there are presently available on the market various orally effective mercurial (D) diuretics including Chlormerodrin (Neohydrin) and Dihydro?umethiazide ___________________ __ 10 to 200 merbiurelidin (Meterox). Such mercurial diuretics suffer 50 Chlormerodrin ________________________ __ 1 to 40 from relatively low absorption from the gastro-intestinal . (E) tract and therefore must be administered at a dose level Chlorthalidone ________________________ __ 10 to 300 which produces gastro-intestinal irritation and side effects. Chlormerodrin __________ _; ____________ __ 1 to 40 According to the present invention it has been dis ' , . (F) covered that by concomitant, and advisably simultaneous, 55 Benzydro?umethiazide __________________ __ 1 to 20 oral administration of a thiazide diuretic and a mercurial diuretic to a human there is achived a much greater, but Chlormerodrin ________________________ __ l to 40 unexpected, diuretic action than could be achieved by ad (G) ministering either of these drugs in the absence of the Methylchlorothiazide ___________________ __ 1 to 20 other. Furthermore, by administering a combination of 60 Chlormerodrin ________________________ __ 1 to 40 a thiazide diuretic and a mercurial diuretic, lower amounts (H) of each drug can be administered to a human than are Trichloromethiazide ____________________ __ 1 to 10 needed when each drug is used separately to obtain an Merbiurelidin _________________________ __ 1 to 40 equal diuretic effect. As a result, the two drugs in com bination can be administered at dosages substantially be 65 A speci?c gelatin capsule could contain 4.0 mg. of trichloromethiazide and 18.5 mg. of chlormerodrin. 3 The diuretic activity of the novel combinations pro surprising when it is considered that the 18.5 in". dose of vided by this invention is illustrated by the results ob chlormerodrin is one-third of the accepted daily dose of tained with six normal human volunteers to Whom 4.0 this drug when administered alone. At such a reduced mg. per day of trichloromethiazide was administered sep dosage, side effects which occur with higher dosages, do arately, and in combination with 118.5 mg. per day of not appear. Furthermore, a daily dose of 18.5 mg. of chlormerodrin. The results of this ?rst test, on an indi-v chlormerodrin alone is recognized to be insu?icient to vidual basis, are as follows with all determinations having signi?cantly increase diuresis and this is shown in the sec been made on 24 hour urine samples: ond test. Thus, essentially no change in urine or sodium output resulted. With respect to potassium, two indi viduals had a signi?cant increase in potassium output. Vol. Percent mEq Percent rnEq Percent 10 (rnL) Vol. Na+ Na+ K“ K“ Compared with the combination of trichloromethiazide Change Change Change and chlormerodrin, the potassium output appeared to be higher with chlormerodrin alone. Thus, chlormerodrin 1.11.13; in non-diuretic doses potentiates the diuretic and natruire Control ______________ -_ 1,365 ______ __ 189 ______ __ 70 ______ __ Triehloromethiatide--- 1,585 +16 212 +12 71 +1 15 tic e?ects of trichlorornethiazide, but at the same time Chlormerodrin+ , inhibits potassium excretion. ’ T'érifghloromethiaZide.-- 2,085 +52 323 +70 64 —10 , . Various changes and modi?cations of the invention can Control ______________ -_ 1,820 ______ __ 203 ______ o- 77 ______ -_ be made and, to the extent that such variations incorpo Trichloromethiazide___ 2,610 +44 283 +40 72 —6 Chlorrnerodrin+ rate the spirit or" this invention, they are intended to be J grghloromethiazide--- 3,140 +72 319 +58 75 0 included Within the scope of the appended claims. , . 20 Control ______________ __ 2,045 ______ __ 204 ______ ._ 93 ______ __ What is claimed is: Trichloromethiazide___ 2,165 +6 315 +54 110 +18 1. The method of increasing diuresis in a human while Chlormerodrh1+ C'¥i-Iiehl0romethiazide___ 2,730 +35 387 +00 101 +8 reducing potassium excretion caused by administration of a thiazide diuretic alone, and without producing the side Control ______________ __ 1,165 ______ __ 130 ______ __ 80 ______ ._ 'I‘richloromethiazide.-- 1,360 +17 239 +85 120 +50 25 effects caused by administration of an orally effective Ghlormerodrin+ mercurial diuretic alone, which comprises orally admin A’I‘ri]e)hlororuethiazide_._ 1,650 +43 214 +65 89 +11 istering to a human a combination of trichloromethiazide Control ______________ -_ 1,110 ______ __ 150 ______ -_ 50 ______ _ Trichloromethiazide___ 1,935 +72 261 +73 70 +40 and chlormerodrin, said combination containing said tri Chlormerodrin+ chloromethiazide in an amount effective to increase di 1jTriq’ohloromethiazide___ 1,720 +55 231 +54 60 +20 uresis and containing the said chlormerodrin in an ‘.1’. .: Control ______________ __ 3,060 ______ __ 196 ______ __ 89 ______ _. amount su?icient to suppress potassium excretion induced Triehloromethiazide.-- 3,125 0 259 +30 116 +30 Ghlormerodrin+ by said trichloromethiazide but in an amount below that Trichloromethiazide_._ 4,305 +33 256‘ +30 106 +17 which causes sufficient adverse side e?ects in the gastro intestinal tract. Subsequently, in a second test, the same six volunteers 35 2. The method of claim 1 wherein the amount of tri were administered the chlormerodrin (18.5 mg.) without chlorometbiazide is 1 to 10 mgs. and the amount of chlor the concomitant administration of trichloromethiazide. merodrin is 1 to 30 mgs. The results are as follows: 3.
Load more

Recommended publications
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Merck & Co., Inc. V. Biocraft Laboratories, Inc
    Merck & Co., Inc. v. Biocraft Laboratories, Inc., 690 F.Supp. 1376 John J. Francis, Jr., Shanley & Fisher, Morristown, N.J., Joseph M. Fitzpatric, Nicholas M. Cannella, Lawrence Alaburda, Salvatore C. Mitri, Fitzpatrick, Cella, Harper & Scinto, New York City, for plaintiff. Glenn A. Clark, Riker, Danzig, Scherer, Hyland & Perretti, Newark, N.J., Donald R. Dunner, Robert D. Bajefsky, Carol P. Einaudi, Sylvia Blickstein, Legal Asst., Finnegan, Henderson, Farabow, Garrett & Dunner, Washington, D.C., for defendant. OPINION POLITAN, District Judge. Plaintiff, Merck & Co., Inc. ("Merck") is a corporation duly organized and existing under the laws of the State of New Jersey. Merck's principal place of business is at 126 Lincoln Avenue, Rahway, New Jersey. Defendant, Biocraft Laboratories, Inc. ("Biocraft") is a corporation duly organized and existing under the laws of the State of Delaware. Biocraft's principal place of business is at 92 Route 46, Elmwood Park, New Jersey. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. § 1338(a). The parties hereto stipulate that each is subject to personal jurisdiction in the United States District Court for the District of New Jersey. Venue is proper in this district by virtue of 28 U.S.C. § 1400(b). Since its issuance, Merck has been the owner by assignment of the entire right, title and interest in the following United States Letters Patent: Number: 3,781,430 (hereinafter referred as to `430"), Issue Date: 12/25/73, Expiration Date: 12/24/90, Applicant: Edward J. Cragoe, Jr., Title: Diuretic Formulations. The validity of this patent is the subject matter of this litigation.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • ARCI Uniform Classification Guidelines for Foreign Substances, Or Similar State Regulatory Guidelines, Shall Be Assigned Points As Follows
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2019 (V.14.0) © ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2019. Association of Racing Commissioners International 2365 Harrodsburg Road- B450 Lexington, Kentucky, USA www.arci.com Page 1 of 66 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]
  • Effect of Mersalyl on the Thick Ascending Limb of Henle's Loop
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 4 (1973). p. 245—251 Effect of mersalyl on the thick ascending limb of Henle's loop MAURICE BURG and NORDICA GREEN Laboratory of Kidney and Electrolyte Metabolism, National Heart andLung Institute, National Institutes of Health, Bethesda, Maryland Effect of mersalyl on the thick ascending limb of Henle's loop. de Henle isolée et perfusee peut être identifié a son effet diuretique The cortical portion of the thick ascending limb of Henle's loop in vivo. Le mersalyl dans Ic bain est inefficace, excepté a une was dissected from rabbit kidneys and perfused in vitro. There concentration plus élevée (10—i M)etalors I'effet n'est pas was active chloride transport resulting in net sodium chloride reversible. Nous concluons que l'effet diurétique des mercuriels reabsorption from the tubule lumen, with the electrical potential est lie, au moms en partie, a l'action inhibitrice de ces drogues difference (PD) oriented positive in the lumen. The addition of sur le transport actif de chlore dans Ia partie large de Ia branche mersalyl ( iO M)tothe lumen caused the PD and net Cl flux ascendante de l'anse de Henle. to decrease, indicating inhibition of the active Cl transport. The decrease in PD caused by the drug in the lumen was approxi- mately 50% at concentrations equal to or greater than iO M, Mercurial diuretics were extensively used and studied andthe decrease in CI transport (measured at 3 x l0 M)was until they were supplanted in the past few years by more similar in magnitude.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • Uniform Classification Guidelines for Foreign Substances, Version 7.00
    Association of Racing Commissioners International, Inc. Drug Testing Standards and Practices Program Model Rules Guidelines Uniform Classification Guidelines for Foreign Substances and Recommended Penalties and Model Rule Version 7.00 Revised January 2014 Association of Racing Commissioners International, Inc. Uniform Classification Guidelines for Foreign Substances Table of Contents Preamble to the Uniform Classification Guidelines of Foreign Substances ..................................................................................... ii Notes Regarding Classification Guidelines ...................................................................................................................................... ii Classification Criteria ....................................................................................................................................................................... iii Classification Definitions ................................................................................................................................................................. iv Drug Classification Scheme ............................................................................................................................................................. vi Alphabetical Substance List ............................................................................................................................................................... 1 Listing by Classification ..................................................................................................................................................................
    [Show full text]